QURE Stock Price
uniQure N.V.
QURE stock price is $20.97 (-1.46% on the day), giving uniQure N.V. a market cap of $1.45B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
QURE Stock Overview
- Price
- $20.97
- Previous close
- $21.28
- Open
- $21.00
- Market cap
- $1.45B
- P/E ratio
- -7.3
- 52-week range
- $8.73 - $71.50
- 1-year price target
- $59.00
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 31
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | QURE | $20.97 | -1.5% | 3.32M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |